Furthermore, among TP53 mut gastric cancer patients, only stage IV patients have higher death risk than stage I patients (4.538 times), while the death risk of TP53 WT patients with stage III and IV is higher than that of stage I patients (2.170 and 3.694 times respectively). Here, TP53 is linked to gastric cancer.